Title: The clinical applicability of percutaneous splenic vein stent implantation for pancreatic
portal hypertension
Version: 2 Date: 11 Feb 2022
Reviewer's report:
Interest in so-called left-sided portal hypertension will always remain among specialists dealing
with the problems of portal hypertension. The authors present their experience in treating
patients with pancreatic portal hypertension, while presenting the results of a promising
minimally invasive treatment.
This is an interesting study examining a relatively large cohort of patients with pancreatic portal
hypertension. The results are interesting, but some important methodological concerns arise.
1.How were the medical co morbidities of these patients being treated? Were any receiving
propranolol or other medications to reduce portal hypertension and risk of upper gastrointestinal
bleeding?
2.How appropriate is it to include the third (conservative) group to compare treatment results,
especially since in the conservative group the authors treat consequences of pancreatitis, and
in the first two groups the treatment is aimed at treating consequences of splenic vein stenosis/
thrombosis and portal hypertension due to chronic pancreatitis.
3. In the discussion of the study results the authors, comparing different treatment methods of
pancreatic portal hypertension, discussing about the negative sides of conservative therapy and
splenectomy, while there are no data on the disadvantages of splenic vein stenting in pancreatic
portal hypertension, neither own nor from the literature.
4. There are a number of minor errors in syntax and grammar, the authors are encouraged to
have the manuscript revised by an English editor
Title: The clinical applicability of percutaneous splenic vein stent implantation for pancreatic
portal hypertension
Version: 2 Date: 11 Feb 2022
Reviewer's report:
Interest in so-called left-sided portal hypertension will always remain among specialists dealing
with the problems of portal hypertension. The authors present their experience in treating
patients with pancreatic portal hypertension, while presenting the results of a promising
minimally invasive treatment.
This is an interesting study examining a relatively large cohort of patients with pancreatic portal
hypertension. The results are interesting, but some important methodological concerns arise.
1.How were the medical co morbidities of these patients being treated? Were any receiving
propranolol or other medications to reduce portal hypertension and risk of upper gastrointestinal
bleeding?
2.How appropriate is it to include the third (conservative) group to compare treatment results,
especially since in the conservative group the authors treat consequences of pancreatitis, and
in the first two groups the treatment is aimed at treating consequences of splenic vein stenosis/
thrombosis and portal hypertension due to chronic pancreatitis.
3. In the discussion of the study results the authors, comparing different treatment methods of
pancreatic portal hypertension, discussing about the negative sides of conservative therapy and
splenectomy, while there are no data on the disadvantages of splenic vein stenting in pancreatic
portal hypertension, neither own nor from the literature.
4. There are a number of minor errors in syntax and grammar, the authors are encouraged to
have the manuscript revised by an English editor
Please review this paper.
user
Title: The clinical applicability of percutaneous splenic vein stent implantation for pancreatic
portal hypertension
Version: 2 Date: 11 Feb 2022
Reviewer's report:
Interest in so-called left-sided portal hypertension will always remain among specialists dealing
with the problems of portal hypertension. The authors present their experience in treating
patients with pancreatic portal hypertension, while presenting the results of a promising
minimally invasive treatment.
This is an interesting study examining a relatively large cohort of patients with pancreatic portal
hypertension. The results are interesting, but some important methodological concerns arise.
1.How were the medical co morbidities of these patients being treated? Were any receiving
propranolol or other medications to reduce portal hypertension and risk of upper gastrointestinal
bleeding?
2.How appropriate is it to include the third (conservative) group to compare treatment results,
especially since in the conservative group the authors treat consequences of pancreatitis, and
in the first two groups the treatment is aimed at treating consequences of splenic vein stenosis/
thrombosis and portal hypertension due to chronic pancreatitis.
3. In the discussion of the study results the authors, comparing different treatment methods of
pancreatic portal hypertension, discussing about the negative sides of conservative therapy and
splenectomy, while there are no data on the disadvantages of splenic vein stenting in pancreatic
portal hypertension, neither own nor from the literature.
4. There are a number of minor errors in syntax and grammar, the authors are encouraged to
have the manuscript revised by an English editor
assistant